MCF7/182R-6 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (14)
- Inventor Info
Info
| Catalogue Number | 152105 |
| Antigen/Gene or Protein Targets | Oestrogen receptor |
| Parental Line | MCF7 S0.5 |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast cancer, fulvestrant resistant |
| Model | Tumour line |
| Relevance | The MCF7/182R-6 Cell line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance. |
| Production Details | The MCF7/182R-6 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 182,780 in 100 nM concentration, see Lykkesfeldt et al (1995). The MCF7/182R-6 cells are grown in the presence of fulvestrant. |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2,5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance. |
| Notes |
Upon withdrawal of fulvestrant, the resistant phenotype is stable and the cells express ER alpha, although at a reduced level. The MCF7/182R-6 cells do not express progesterone receptor. The MCF7/182R-6 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 421 (AL2533, AL2536) In mice, estrogen supplementation is required for formation of tumours, and treatment with ICI 182,780 inhibits tumour growth. This model is considered an in vitro model. The fulvestrant resistant cells have progressed towards reduced estrogen dependence and unpublished in vivo experiments indicate that fulvestrant resistant xenografts may be established by inoculation of MCF-7/182R-6 cells in animals treated with estrogen and then treatment with fulvestrant until regrowth of the tumor. |
| Cellosaurus ID | CVCL_W536 |
References: 14 entries
Thrane et al. 2014. Oncogene. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Europe PMC ID: 25362855
Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-13. PMID: 19697122.
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
Europe PMC ID: 19697122
Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071.
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Europe PMC ID: 18409071
Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.
Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Europe PMC ID: 17061041
Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.
Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Europe PMC ID: 16172194
Nabha et al. 2005. Oncogene. 24(19):3166-76. PMID: 15735693.
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
Europe PMC ID: 15735693
Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Europe PMC ID: 7759159
Add a reference
References: 14 entries
Thrane et al. 2014. Oncogene. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-13. PMID: 19697122.
Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-75. PMID: 18409071.
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.
Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frogne et al. 2005. Endocr Relat Cancer. 12(3):599-614. PMID: 16172194.
Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Nabha et al. 2005. Oncogene. 24(19):3166-76. PMID: 15735693.
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.
Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
Add a reference
